^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    telatinib (BAY 57- 9352)

    i
    Other names: BAY 57- 9352, EOC315, TEL0805
    Associations
    News

    Trials

    Company:
    Edding Genor Group
    Drug class:
    VEGFR inhibitor, c-KIT inhibitor, PDGFR inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (NCT04798781)
    Phase 2
    Andrew Hendifar, MD
    Active, not recruiting
    Last update posted :
    03/07/2024
    Initiation :
    07/28/2021
    Primary completion :
    02/14/2024
    Completion :
    02/14/2025
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer (NCT03817411)
    Phase 2
    Taizhou EOC Pharma Co., Ltd.
    Unknown status
    Last update posted :
    05/07/2019
    Initiation :
    01/25/2019
    Primary completion :
    03/30/2020
    Completion :
    01/25/2021
    HER-2
    |
    HER-2 negative
    |
    capecitabine • oxaliplatin • telatinib (BAY 57- 9352)